US 11,793,781 B2
Autoimmune disorder treatment using RXR agonists
Roshantha A. Chandraratna, San Juan Capistrano, CA (US); Ethan Dmitrovsky, Hanover, NH (US); Elizabeth Nowak, West Lebanon, NH (US); and Randolph Noelle, Plainfield, NH (US)
Assigned to Io Therapeutics, Inc., Spring, TX (US); and Trustees of Dartmouth College, Hanover, NH (US)
Filed by Io Therapeutics, Inc., Spring, TX (US); and Trustees of Dartmouth College, Hanover, NH (US)
Filed on Jan. 27, 2022, as Appl. No. 17/586,657.
Application 17/586,657 is a continuation of application No. 17/126,787, filed on Dec. 18, 2020, granted, now 11,246,845.
Application 17/126,787 is a continuation of application No. 16/742,616, filed on Jan. 14, 2020.
Application 16/742,616 is a continuation of application No. 16/228,217, filed on Dec. 20, 2018, granted, now 10,945,976, issued on Mar. 16, 2021.
Application 16/228,217 is a continuation of application No. 15/852,580, filed on Dec. 22, 2017, granted, now 10,201,512, issued on Feb. 12, 2019.
Application 15/852,580 is a continuation of application No. 15/341,969, filed on Nov. 2, 2016, granted, now 10,285,960, issued on May 14, 2019.
Application 15/341,969 is a continuation of application No. 13/714,051, filed on Dec. 13, 2012, abandoned.
Claims priority of provisional application 61/570,182, filed on Dec. 13, 2011.
Prior Publication US 2022/0151964 A1, May 19, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/192 (2006.01); A61K 31/216 (2006.01); A61K 31/201 (2006.01); A61K 31/353 (2006.01); A61K 31/343 (2006.01); A61K 31/47 (2006.01); A61K 31/4704 (2006.01); A61K 9/00 (2006.01)
CPC A61K 31/192 (2013.01) [A61K 9/0073 (2013.01); A61K 31/201 (2013.01); A61K 31/216 (2013.01); A61K 31/343 (2013.01); A61K 31/353 (2013.01); A61K 31/47 (2013.01); A61K 31/4704 (2013.01); Y02A 50/30 (2018.01)] 23 Claims
 
1. A method of treating an autoimmune gastrointestinal disorder, wherein the autoimmune gastrointestinal disorder is an inflammatory bowel disease or celiac disease, the method comprising elevating Treg cell numbers and suppressing Th17 cell numbers in an individual having the autoimmune gastrointestinal disorder by administering a therapeutically effective amount of a retinoid X receptor (RXR) agonist having the structure of formula XII:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof;
wherein R is H or lower alkyl of 1 to 6 carbons;
wherein the therapeutically effective amount is about 0.001 mg/kg/day to about 100 mg/kg/day;
wherein the inflammatory bowel disease is ulcerative colitis or Crohn's disease; and
whereby the balance between Treg and Th17 cell development is modulated to restrain autoimmunity.